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Increased demand for amino acids to sustain acute-phase
protein synthesis could be the stimulus for the increased
muscle protein catabolism during hemodialysis (HD). This
could be attenuated by intradialytic amino-acid infusion. To
test this, we measured the fractional synthesis rates of
albumin, fibrinogen, and muscle protein in eight patients
with end-stage renal disease at baseline before dialysis and
during HD without or with amino-acid infusion. The
percentage change in the fractional synthesis rates of
albumin, fibrinogen, and muscle protein from baseline was
significantly higher during HD with amino-acid infusion than
without amino-acid infusion. Leg muscle proteolysis was
significantly increased during unsupplemented HD compared
with baseline, but this was not decreased by amino-acid
infusion. Arteriovenous balance studies across the leg
showed a net efflux of interleukin-6 (IL-6) from the muscle
into the vein during HD. The fractional synthesis rate of
albumin, fibrinogen, and muscle protein correlated with each
other and with the IL-6 efflux from the leg. Leg muscle
protein catabolism was positively related to IL-6 release from
the leg and not associated with amino-acid availability. Our
results show that intradialytic cytokine activation and not
amino-acid depletion is the major protein catabolic signal
during HD.
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Loss of lean body mass, decreased serum albumin, and
elevated fibrinogen level are important predictors of
mortality and morbidity in the general population and in
patients with end-stage renal disease (ESRD). Change in
concentration of any protein in plasma is the consequence of
variations in the rates of synthesis, catabolism, external
losses, and volume of distribution of the protein. In healthy
humans, albumin and fibrinogen account for B50 and
B10% of the total liver protein synthesis, respectively.1
Under normal conditions hepatic synthesis of plasma
proteins does not work at the limit of its functional capacity.
Rothschild et al.2 calculated that under normal conditions,
the liver works at about 30% of its synthetic capacity. Protein
synthesis is influenced by a number of factors including
nutrition, inflammation, stress, metabolic acidosis, age,
hormones, exercise, altitude, and posture. Nutritional
stimulation of albumin synthesis has been demonstrated
both acutely after the consumption of meal and chronically
in response to a high-protein diet.3 Protein kinetics and
acute-phase response is modulated by the interaction
between nutritional status and inflammation.4,5 Although
albumin is catabolized in a mass-dependent manner, the
catabolic rate of fibrinogen remains constant despite
considerable variations in the circulating mass of fibrinogen.
In some physiological and pathological conditions, there is
a concomitant increase in the fractional synthesis rates
(FSRs) of albumin, fibrinogen, and muscle protein, but in
others the responses may be discordant.6,7 In our previous
work, we showed that hemodialysis (HD) induces a
coordinated increase in FSRs of albumin, fibrinogen, and
muscle protein.8 Regional leg protein kinetics, however,
showed enhanced protein breakdown with inadequate
compensatory increase in synthesis during HD.8 We con-
cluded that increased demand for amino acids mainly for
acute-phase protein synthesis intradialysis is a potential
stimulus for the increased muscle protein catabolism and
efflux of amino acids from the muscle.8 Recently, we showed
that amino-acid infusion during HD increases muscle
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protein synthesis but does not ameliorate protein break-
down.9 We speculated that the unabated protein catabolism
despite amino-acid repletion during HD could be due to the
concomitant activation of cytokines and stress hormones.9
This study was designed to examine the effect of amino-acid
infusion and cytokine activation on hepatic and muscle
protein kinetics during HD (Figure 1).
RESULTS
The clinical and biochemical characteristics of the subjects
are shown in Table 1. The etiology of renal failure was
hypertension in three, glomerulonephritis in two, tubuloin-
terstitial nephropathy in one, and unknown in three patients.
The total amount of amino acid infused during hemodialysis
with amino-acid infusion (HDþAA) was 16.2±2.4 g.
Amino-acid loss during HDþAA was more than the loss
during hemodialysis without amino-acid infusion (HD-O)
(7.5±1.1 vs 4.2±0.9 g, Po0.01). Glucose, insulin, and
cortisol levels increased significantly during HDþAA. The
urea reduction ratio was 56.7±3.2%.
The precursor phenylalanine reached an isotopic plateau
at 240 min and remained stable throughout the experiment.
Enrichments of protein-bound phenylalanine in albumin,
fibrinogen, and muscle protein are shown in Table 2.
Enrichment in all the three compartments (artery, vein,
and muscle-free pool) decreased significantly during
HDþAA compared with pre-HD and HD-O. Enrichment
within each phase of the study, however, remained stable,
thus maintaining a steady state. Enrichment of albumin and
fibrinogen progressively increased during HD-O and
HDþAA (Po0.01) (Table 2). FSRs of albumin and
fibrinogen increased progressively and significantly during
HD-O and further during HDþAA from baseline
(Figures 2 and 3). The muscle protein-bound phenylalanine
increased during HD-O and HDþAA (Po0.001), and the
intracellular phenylalanine enrichment decreased during
HDþAA compared with HD-O (Po0.01). FSR of muscle
protein increased during HD-O compared with pre-HD and
furthermore during HDþAA (Po0.001) (Figure 4).
Amino-acid entry into the leg and also efflux from the leg
increased significantly during HDþAA. Amino-acid efflux
from the leg was higher than the inflow during HD-O and
HDþAA (Po0.01) (Table 3). The net amino-acid balance
became negative during HD-O and did not change
significantly during HDþAA. Leg muscle protein breakdown
was higher than leg muscle protein synthesis during HD-O
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Figure 1 | Study design. ESRD patients were studied before hemodialysis (pre-HD, postabsorptive phase, 0–300 min) and during HD
(300–540 min). HD phase was further divided into an initial 2 h of HD without amino-acid infusion (HD-O, 300–420 min) and a subsequent 2 h
during which the patients received a primed constant infusion of unlabeled amino-acid mixture (HDþAA, 420–540 min). After obtaining blood
samples for background enrichment at 0 min, a primed continuous infusion of L-(ring 13C6) phenylalanine was started and continued
throughout the experiment. From 240 to 300 min, 360 to 420 min, and from 480 to 540 min, blood samples were obtained from the artery and
the vein to estimate enrichment and arteriovenous (AV) balance and to measure protein kinetics. Muscle biopsies were obtained at baseline,
300 min, 420 min, and 540 min. A continuous infusion of indocyanin green was administered into the femoral artery between 240–270 min,
360–390 min, and 480–510 min to estimate the blood flow rate to the leg.
Table 1 | Clinical and biochemical profile of study participants
Pre-HD HD-O HD+AA
Age years) 42.7±4.1
Male/female 7/1
Weight (kg) 78.1±6.9 75.5±5.3
Hemoglobin (g per 100 ml) 12.5±0.6 12.8±0.8 12.6±0.5
Sodium (mequiv. l1) 132.7±3.5 134.6±5.4 135.3±6.0
Potassium (mequiv. l1) 5.6±0.5a 3.4±0.5 4.1±0.4
HCO3 (mequiv. l
1) 21.3±0.5a 23.2±0.6 25.1±0.7
BUN (mg per 100 ml) 57.2±5.0a 34.3±4.4b 26.1±3.7
Creatinine (mg per 100 ml) 9.3±0.4a 7.4±0.5b 5.9±0.4
Albumin (g per 100 ml) 3.6±0.03 3.5±0.09 3.6±0.06
Fibrinogen (g l1) 326.1±21.9 405.1±30.7 413.1±44.8
Glucose (mg per100 ml) 115.1±4.5 124.2±7.0 130.9±7.3c
Insulin (mU per 100 ml) 10.3±1.4 12.6±2.5 19.8±2.6d
Cortisol (mg per 100 ml) 10.3±1.1 12.6±2.2 16.8±3.0d
BUN, blood urea nitrogen; HD+AA, hemodialysis with amino-acid infusion; HD-O,
hemodialysis without amino-acid infusion; Pre-HD, before hemodialysis.
aPo0.001 pre-HD vs HD-O and HD+AA.
bPo0.01 HD-O vs HD+AA.
cPo0.05 HD+AA vs pre-HD.
dPo0.01 HD+AA vs pre-HD and HD-O.
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(Po0.001). Both protein synthesis and breakdown increased
during amino-acid infusion (Po0.001), but the net amino-
acid balance remained negative during HDþAA.
The concentration of cytokines in the artery and vein
increased over a variable level during HD-O and HDþAA
(Table 4). Venous concentration of IL-6 was significantly
higher than that in the artery. Net release of IL-6 from the leg
(pg min1 per 100 ml per leg) increased progressively during
HD-O (17.19±3.78) and HDþAA (35.84±7.32) from
baseline (3.30±2.44) (Po0.001 HDþAA vs pre-HD and
HD-O; Po0.001 HD-O vs pre-HD). The concentration
of IL-6-soluble receptor (gp80) and gp130 in the vein also
increased significantly during HD-O and HDþAA from
baseline. A significant and positive correlation between FSRs
of albumin, fibrinogen, and muscle protein and arterio-
venous balance of IL-6 was noted (Table 5). There was no
association between phenylalanine concentration in the
artery and FSRs. Leg protein catabolism was positively and
significantly related to arteriovenous balance of IL-6.
DISCUSSION
To determine the effect of amino-acid repletion on hepatic
and muscle protein synthesis, we measured the FSRs of
albumin, fibrinogen, and muscle protein in eight ESRD
patients at baseline and during 2 h of HD without amino-
acid infusion and a subsequent 2 h of HD with amino-acid
infusion. FSRs of albumin, fibrinogen, and muscle protein
increased during HD-O. With amino-acid repletion during
HDþAA, the FSRs increased more significantly. Leg muscle
protein catabolism far exceeded synthesis, resulting in net
protein loss during HD-O. Net balance improved signifi-
cantly during HDþAA but did not become positive. IL-6
efflux from the muscle into the vein increased progressively
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Figure 2 | Fractional synthesis rate of albumin before (pre-HD),
during hemodialysis (HD), without (HD-O), and with
amino-acid infusion (HDþAA). wPo0.001 HD-O vs pre-HD,
zPo0.001 HDþAA vs pre-HD, and HD-O.
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Figure 4 | Fractional synthesis rate of muscle protein before
(pre-HD), during hemodialysis (HD), without (HD-O), and with
amino-acid infusion (HDþAA). wPo0.001 HD-O vs pre-HD,
zPo0.001 HDþAA vs pre-HD, and HD-O.
Table 2 | Free amino-acid enrichment in different compartments
Pre-HD HD-O HD+AA
Artery 0.116±0.006 0.124±0.004a 0.096±0.003b
Vein 0.103±0.004 0.100±0.005 0.076±0.004b
Albumin 0.0208±0.0011 0.0271±0.0014c 0.0364±0.0021d
Fibrinogen 0.0367±0.0055 0.0432±0.0053c 0.0573±0.0061d
Muscle-free pool 0.070±0.006 0.072±0.006 0.064±0.004e
Muscle 0.000328±0.000007 0.000353±0.00001c 0.000486±0.00002f
HD+AA, hemodialysis with amino-acid infusion; HD-O, hemodialysis without amino-acid infusion; Pre-HD, before hemodialysis.
aPo0.001 HD-O vs pre-HD.
bPo0.001 HD+AA vs pre-HD and HD-O.
cPo0.01 HD-O vs pre-HD.
dPo0.01 HD+AA vs pre-HD and HD-O.
ePo0.01 HD+AA vs HD-O.
fPo0.001 HD+AA vs pre-HD and HD-O.
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Figure 3 | Fractional synthesis rate of fibrinogen before
(pre-HD), during hemodialysis (HD), without (HD-O), and with
amino-acid infusion (HDþAA). wPo0.001 HD-O vs pre-HD,
zPo0.001 HDþAA vs pre-HD, and HD-O.
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during HD-O and HDþAA and correlated positively with
the FSRs and muscle protein catabolism. Interestingly,
amino-acid concentration in the artery was not positively
related to protein synthesis or negatively associated with
protein catabolism. These results indicate that increased
amino-acid demand or amino-acid depletion itself is unlikely
to be the sole catabolic signal for protein breakdown
during HD.9 It is possible that the accompanying cytokine
activation overrides the anabolic response to amino-acid
supplementation.
Renal failure per se does not produce a gross defect in
the capacity of patients to have a normal rate of albumin
synthesis or to respond to external losses of albumin.10
Giordano et al.11 observed that fractional synthesis rates of
albumin and fibrinogen in ESRD patients with normal
nutritional status are not different from controls. Kaysen
et al.12 demonstrated that albumin synthesis rate is decreased
only in ESRD patients with hypoalbuminemia. Results from
our laboratory as well as from other investigators have shown
that FSRs of albumin and fibrinogen increase intradialysis
despite decline in plasma levels of amino acids.8,13 Tjiong
et al.14 reported that amino acid-based dialysate does not
increase FSR-A either in the fasting or the fed state in
peritoneal dialysis patients. Pupim et al.15 showed that
intradialytic parenteral nutrition improves the fractional
synthesis rate of albumin. In this study, however, FSRs of
fibrinogen or muscle protein were not measured simulta-
neously. This study demonstrates that amino-acid repletion
during HD increases the synthesis rates of albumin,
fibrinogen, and muscle protein. Availability of amino acids
is an important rate-limiting factor in protein synthesis.
Grimble16 suggested that acute-phase protein synthesis may
Table 3 | Arteriovenous balance of amino acids and leg muscle protein kinetics
Pre-HD HD-O HD+AA
Phenylalanine
Concentration in artery 117.6±2.2a 103.1±4.0 131.2±3.6b
Concentration in vein 121.1±2.9c 113.0±3.1d 133.9±2.4b
Concentration in muscle-free pool 135.1±3.0e 128.1±3.1e 146.9±3.2b,e
Amino-acid inflow 471.82±43.39 417.96±36.11 538.94±32.61f
Amino-acid efflux 468.3±43.96 447.84±36.35g 559.60±32.32f,h
Net balance 3.51±2.64i 29.88±4.70 20.66±4.07
Branched chain amino acid
Amino-acid inflow 1222.76±107.70 1012.81±82.79 2090.81±161.51b
Amino-acid efflux 1222.52±112.93 1107.23±91.84g 2143.24±160.35b,h
Net balance 0.25±11.00i 94.42±12.60 52.43±15.86
Essential amino acid
Amino-acid inflow 3418.68±274.65 2732.63±194.47 4723.42±320.52b
Amino-acid efflux 3404.13±278.94 3030.36±229.66g 4949.96±323.04b,h
Net balance 14.55±37.60i 297.73±47.47 226.54±52.70
Total amino acid
Amino-acid inflow 12147.1±859.9a 9202.71±649.8 13308.86±884.0 j
Amino-acid efflux 12245.12±878.31 10140.06±735.0g 13860.17±888.9k,l
Net balance 98.05±124.04m 937.34±168.14 551.31±250.0
Regional kinetics
Leg muscle protein synthesis 48.32±3.65 53.56±3.34 87.21±3.87b
Leg muscle proteolysis 54.37±5.00 91.39±4.56n,o 108.25±4.54b,p
Net protein loss 6.05±2.37i 33.65±1.52q 16.86±1.78
HD+AA, hemodialysis with amino-acid infusion; HD-O, hemodialysis without amino-acid infusion; Pre-HD, before hemodialysis.
Data expressed as nmol min1 100 ml per leg.
aPo0.001 pre-HD vs HD-O.
bPo0.001 HD+AA vs pre-HD and HD-O.
cPo0.01 pre-HD vs HD-O.
dPo0.001 concentration in artery vs concentration in vein;
ePo0.001 concentration in muscle-free pool vs concentrations in artery and vein.
fPo0.01 HD+AA vs pre-HD.
gPo0.001 amino-acid inflow vs outflow.
hPo0.01 amino-acid inflow vs outflow.
iPo0.001 pre-HD vs HD-O and HD+AA.
jPo0.01 HD+AA vs pre-HD and HD-O.
kPo0.02 HD+AA vs HD-O.
lPo0.05 amino-acid inflow vs outflow.
mPo0.02 pre-HD vs HD-O.
nPo0.001 HD-O vs pre-HD.
oPo0.001 leg muscle proteolysis vs synthesis.
pPo0.05 leg muscle proteolysis vs synthesis.
qPo0.001 HD-O vs HD+AA.
Kidney International (2008) 73, 1054–1061 1057
DSC Raj et al.: Acute-phase protein synthesis in ESRD o r i g i n a l a r t i c l e
introduce an additional demand for the metabolically
interrelated amino acids, such as glycine, serine, methionine,
and cystine. However, Reeds et al.17 suggested that as acute-
phase proteins are not rich in sulfur amino acids, it is the
availability of aromatic amino acids that could be rate
limiting. Mortimore and Posco18 demonstrated that trypto-
phan, arginine, ornithine, lysine, phenylalanine, glutamine,
alanine, threonine, and proline induce hepatic protein
synthesis, but leucine, valine, methionine, and histidine had
an insignificant effect. We used predominantly essential
amino acids enriched with glutamine to replete the blood and
muscle compartments. Glutamine was included because of its
effect on acute-phase protein synthesis.19 Insulin, thyroid
hormone, growth hormone, and glucocorticoids are all
necessary to maintain a normal basal rate of albumin
synthesis.20,21 De Feo et al.22 observed that insulin deficiency
is associated with a decrease in albumin synthesis but an
increase in fibrinogen synthesis.
There seems to be a somatic–splanchnic recycling of
amino acids;23,24 in catabolic states and starvation, amino
acids are released from the muscle into the blood to be used
in other organs. In this study, an increase in leg protein
breakdown was noted during HD-O, which was associated
with a net efflux of amino acid from muscle into the vein.
With amino-acid repletion (HDþAA), there was a balanced
increase in both synthesis and catabolism. Amino-acid
balance across the leg became less negative during HDþAA
but did not shift from net release to net uptake. This could be
due to the inefficient utilization of amino acids for protein
synthesis due to concomitant cytokine activation.9 The
amino acids released from the muscle are used to sustain
augmented acute-phase protein synthesis in the liver.8 IL-6 is
a pleiotropic cytokine involved in the mediation of acute-
phase reaction and muscle protein catabolism.8,25 Cytokines
are known to mediate protein breakdown through the
activation of both lysosomal (cathepsin) and nonlysosomal
(proteasome) pathways.26–28 Furthermore, anticytokine treat-
ments have been shown to effectively reduce muscle protein
loss by downregulating the activity of the two major
proteolytic systems.28,29
IL-6 efflux from the muscle and also plasma levels of IL-6,
gp80, and gp130 increased significantly during HD-O and
HDþAA. IL-6 mediates its effects on target cells through a
complex receptor system composed of a ligand-binding
subunit (sIL-6R or gp80) and a signal-transducing glyco-
protein (gp130). Although peripheral blood mononuclear
cells are an established source of inflammatory cytokines
during HD,30 skeletal muscle is also capable of generating
these biomolecules.31 Muscle-derived IL-6 functions as an
exocrine hormone, exerting its effect on the liver and adipose
tissue.32 FSRs of albumin, fibrinogen, and muscle protein
correlated positively with each other and also with IL-6
balance across the leg. Barle et al.33 demonstrated that
albumin synthesis increases in the very early phase after a
challenge with endotoxin. Ballmer et al.34 showed that
proinflammatory cytokines stimulated total liver protein
synthesis, but decreased albumin synthesis rate and also
inhibited nutrient-induced increase in albumin synthesis.
However, albumin synthesis was not decreased in cancer
patients with evidence of an ongoing acute-phase protein
response.35 Head trauma induces opposite and large changes
of protein synthesis in the muscle and acute-phase hepatic
proteins, probably mediated by cytokines.36
To summarize, FSRs of albumin and fibrinogen increase
during HD-O, which is facilitated by the constant delivery of
amino acids derived from the muscle catabolism and
Table 4 | Cytokine efflux from the muscle into the vein
Pre-HD HD-O HD+AA
Interleukin-1 (pg per 100 ml)
Femoral artery 0.19±0.03a 0.24±0.03 0.27±0.03
Femoral vein 0.23±0.02 0.26±0.03 0.29±0.03b
Interleukin-6 (pg per 100 ml)
Femoral artery 4.63±0.70c 14.45±1.58 16.32±16.32
Femoral vein 5.56±0.93c 18.38±1.18d 24.44±1.43d,e
Tumor necrosis factor-a (pg per 100 ml)
Femoral artery 1.02±0.10f 1.20±0.15 1.21±0.13
Femoral vein 1.02±0.12f 1.27±0.19 1.32±0.16
IL-6 gp130
(ng per 100 ml)g
247.60±29.41c 382.74±29.86 431.53±31.16
IL-6 Soluble receptor
(ng per 100 ml)g
44.59±3.94a 57.62±2.50 62.93±4.30
hsCRP (mg l1)g 1.08±0.34f 1.62±0.30 1.78±0.46
HD+AA, hemodialysis with amino-acid infusion; HD-O, hemodialysis without amino-
acid infusion; hsCRP, high sensitivity C-reactive protein; Pre-HD, before hemodialysis;
IL-6, Interleukin-6.
aPo0.01 pre-HD vs HD-O and HD+AA.
bPo0.05 HD+AA vs Pre-HD and HD-O.
cPo0.001 pre-HD vs HD-O and HD+AA.
dPo0.01 Artery vs Vein.
ePo0.01 HD+AA vs HD-O.
fPo0.05 pre-HD vs HD-O and HD+AA.
gConcentration in vein.
Table 5 | Pearson product moment correlation between
variables
Fibrinogen Muscle Catabolism Phenylalanine IL-6
Albumin 0.869 0.903 0.754 0.221 0.545
0.000 0.000 0.000 0.299 0.005
Fibrinogen 0.879 0.664 0.130 0.695
0.000 0.001 0.544 0.000
Muscle 0.859 0.209 0.601
0.000 0.326 0.002
Catabolism 0.146 0.449
0.495 0.027
Phenylalanine 0.326
0.120
Under each category first row is correlation and second row is p.
Albumin, fractional synthesis rate of albumin; Catabolism, muscle protein catabolism
determined by regional kinetics; Fibrinogen, fractional synthesis rate of fibrinogen;
IL-6, arterio-venous balance of interleukin-6; Muscle, fractional synthesis rate of
muscle; Phenylalanine, concentration of phenylalanine in the artery.
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intradialytic increase in IL-6. The provision of exogenous
amino-acid substrate to support hepatic acute-phase protein
synthesis, improved protein balance through augmented
muscle protein synthesis but did not decrease muscle
proteolysis. A positive relationship between IL-6 and muscle
protein catabolism, and a lack of correlation between these
parameters and amino-acid availability indicate that cytokine
activation during HD directly or indirectly overrides the
potential suppressive effect of the amino-acid supplement on
proteolysis. Thus, future interventions aimed at achieving net
protein anabolism during HD should provide amino-acid
substrate as well as attenuate the generation of proinflam-
matory cytokines intradialysis.
MATERIALS AND METHODS
Subjects
Eight stable ESRD patients on maintenance HD for more than 90
days were studied. Patients with diabetes mellitus, infection, chronic
inflammation, pregnancy, hematocrit o30%, bleeding diathesis,
preexisting cardiac condition, hepatic disease, catabolic illnesses, or
unexplained weight loss were excluded from the study. The study
was approved by the Human Research Review Committee at the
University of New Mexico Health Sciences Center (UNMHSC).
Patients were studied at baseline (pre-HD), during 2 h of HD
without amino-acid infusion (HD-O), and 2 h of HD with amino-
acid infusion (HDþAA).
Methods
Patients were placed on a diet containing 35 kcal kg1, 1.2 g protein
per kg day1 for a minimum of 14 days before the study. Patients
were admitted to the General Clinical Research Center (GCRC) at
the UNMHSC 1 day before the experiment. Leg volume was
estimated as described before.37 The study was performed in a
postabsorptive state after an overnight fast. Polyethylene catheters
were inserted in the femoral artery and vein on the same side. The
femoral arterial catheter was used for the infusion of indocianin
green. Catheters were also placed in the nonaccess forearm veins for
infusion of labeled amino acids and in the right wrist vein for
arterialized blood sampling.
After obtaining a blood sample for background amino-acid
enrichment, a primed continuous infusion of L (ring 13C6)
phenylalanine (prime 2.0mmol kg1, infusion 0.05mmol kg1 min1)
was maintained throughout the experiment (Figure 1). Tracer infusion
rates were increased by 10% during HDþAA to maintain stable
enrichment. Blood flow to the lower extremity was measured by dye
dilution technique.38
HD was initiated after 300 min of isotope infusion and
continued for 4 h. Patients were dialyzed using their usual blood
and dialysate flow rates. A new polysulfone membrane (Hemoflow
F70; Fresenius, Hemoflow, Lexington, MA, USA) was used for
dialysis. Anticoagulation was not used to minimize the risk of
bleeding. During the last 2 h of dialysis, a primed (50 ml) constant
infusion (125 ml h1) of unlabeled amino-acid mixture was
maintained through the venous port of the dialysis circuit. The
amino-acid mixture was prepared from commercial amino-acid
preparation (10% TrophAmine; Braun Medical, Irvine, CA, USA) to
which freshly prepared glutamine was added. The final concentra-
tion of amino acids in the infusate was as follows: alanine 2.51 g l1,
arginine 5.64 g l1, aspartic acid 1.48 g l1, cysteine 0.11 g l1,
glutamine 6.68 g l1, glycine 1.69 g l1, glutamate 1.96 g l1, histidine
2.25 g l1, isoleucine 3.82 g l1, leucine 6.54 g l1, lysine 3.82 g l1,
methionine 1.58 g l1, phenylalanine 2.25 g l1, proline 3.18 g l1,
serine 1.78 g l1, taurine 0.12 g l1, threonine 1.95 g l1, tryptophan
0.94 g l1, tyrosine 1.22 g l1 and valine 3.65 g l1. Representative
dialysate samples were collected every 10 min in a sterile container.
The samples were collected separately during HD-O and HDþAA.
Muscle biopsies were performed at the second hour to measure
isotopic carbon enrichment of bound and free phenylalanine in the
muscle. Subsequent biopsies were obtained at the fifth, seventh, and
ninth hours of the experiment to determine the intracellular
enrichments and to calculate the fractional synthesis rate of protein
during pre-HD, HD-O, and HDþAA, respectively. Biopsies were
taken from the lateral portion of the vastus lateralis about 20 cm
above the knee using a Bergstrom biopsy needle.
Blood samples were obtained at baseline and during the last
10 min of HD-O and HDþAA for blood urea nitrogen, creatinine,
electrolytes, albumin, and fibrinogen. Samples were also collected to
determine the arteriovenous balance of amino acids and cytokines.
Albumin was measured by the bromcresol green method, glucagon
by radioimmunoassay and insulin, and cortisol and C-reactive
protein by immulite chemiluminescence. Plasma cytokines were
measured using standard ELISA kits (R&D System, Minneapolis,
MN, USA); Soluble IL-6 receptor (sIL-6R, gp80) using kits from
Bender MedSystem (Burlingame, CA, USA) as per the manufac-
turer’s directions. All measurements were carried out in triplicates
and the mean value was used.
Analytical methods
Blood. Amino acids were separated using cation-exchange chro-
matography and dried under vacuum using Speed-Vac.39 The
enrichment of free amino acids in the plasma sample was
determined by gas chromatography mass spectrometry (GCMS)
(GC HP 5890, MSD HP 5989; Hewlett Packard, Palo Alto, CA, USA)
by selected ion (mass to charge ratio, m/z) monitoring. Chemical
ionization was used for nitrogen-acetyl-n-propyl esters derivatives of
phenylalanine (m/z 336, 342, and 346). Data are expressed as tracer/
tracee ratio. Free amino-acid concentration in arterial and venous
blood samples was determined by HPLC (Waters 2960 system;
Milford, MA, USA) and precolumn derivatization and orthophtha-
laldehyde and 3-mercaptopropionic acid.
Albumin and fibrinogen. Albumin was isolated by ethanol
extraction from trichloroacetic acid precipitated plasma proteins as
described previously.40 In short, citrated plasma was precipitated
with 10% trichloroacetic acid, centrifuged, and supernatant
discarded. The protein pellet was dissolved in absolute alcohol.
The resulting supernatant was decanted to obtain isolated plasma
albumin. The pellet was dried under vacuum. Albumin was
hydrolyzed at 110 1C for 24 h with 6 N constant boiling hydrochloric
acid. The protein hydrolysates were passed through a cation-
exchange column to isolate purified amino acids. nitrogen-acetyl-n-
propyl esters derivatives of the purified albumin amino
acids were then separated and analyzed by GCMS. L-(ring 13C6)
phenylalanine enrichment of albumin was determined from the
mþ 6/mþ 3 ratio and an isotopic dilution curve.
To determine isotopic enrichment in fibrinogen, blood
samples were transferred into heparin sodium-treated tubes and
centrifuged at 4 1C. Fibrinogen was precipitated from 2 ml plasma by
adding 40 ml calcium chloride (1 M) and four units of thrombin
and incubating at 22 1C for 2 h.41 The clot was washed and
centrifuged. The purity of the isolate was confirmed by SDS gel
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electrophoresis. The resulting pellet was analyzed for phenylalanine
enrichment as described before.
Muscle
Muscle samples were weighed and protein precipitated with 500 ml
of 14% perchloric acid. The supernatant was collected after
homogenization of the issue and centrifugation. The amino acids
in the pooled supernatant were separated using cation-exchange
chromatography. The isotopic enrichment of the intracellular amino
acid was determined on their nitrogen-acetyl-n-propyl esters
derivatives in the electron impact mode. Intracellular enrichment
was corrected on the basis of the chloride method.42 The tissue pellet
was further washed with saline and absolute alcohol and dried at
50 1C overnight. The precipitated protein was hydrolyzed at 110 1C
for 24 h with 6 N constant boiling HCl. The protein hydrolysate was
then processed as blood samples, and phenylalanine enrichment was
measured by GCMS (GC 8000 series, MD 800; Fisons Instruments,
Manchester, UK) using chemical ionization and the standard curve
approach.43
Calculations
Amino acids entering the leg through the femoral artery and leaving
the leg through the femoral vein were estimated as
Amino-acid inflow¼ concentration in artery plasma flow rate
Amino-acid efflux¼ concentration in vein plasma flow rate
Net amino-acid balance in the leg was calculated as:
Net balance¼ (concentration in arteryconcentration in
vein) plasma flow rate
The rate of disposal of arterial phenylalanine is an index of the
absolute amount of protein synthesis.
Rate of disposal¼ ((enrichment in artery concentration in
arteryenrichment in vein concentration in vein)/enrichment in
artery) plasma flow rate
The rate of appearance of phenylalanine is an estimate of protein
degradation. Rate of appearance was calculated as
Rate of appearance¼ rate of disposalnet balance.
FSR of muscle protein was calculated by dividing the increment
in enrichment in the product (DEP) by the average in the
intracellular enrichment (precursor) from the first and second
muscle biopsies. DEP is the difference in the enrichment of the
muscle protein between the first and second muscle biopsies. The
use of intracellular amino-acid enrichment as a precursor of protein
synthesis has been validated by in vivo studies.44
FSR-A and FSR-F (% hour) were calculated as reported by us
earlier.45
Statistics
Data are given as mean±s.e.m. a was set at 0.05. Student’s paired
and unpaired ‘t’ tests were used as appropriate. A repeated
measure of analysis of variance with a post hoc Tukey test or
Kruskal–Wallis analysis of variance on ranks was used when
comparing more than two variables. Pearson product moment
correlation was used to measure the strength of linear relationship
between variables.
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